Viewing data from:

AUGMENTIN ES-600

NDA

AMOXICILLIN; CLAVULANATE POTASSIUM | N050755 | US ANTIBIOTICS LLC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

1 petition from Regulations.gov

Petition	Type	Filed	Status	Petitioner
Aurobindo Pharmaceuticals Limited (EAS Consulting Group) - Citizen Petition FDA-2010-P-0177 · 5 docket documents Aurobindo Pharmaceuticals Limited, through EAS Consulting Group, filed this citizen petition on March 26, 2010, requesting that the FDA determine whether Augmentin ES-600 (amoxicillin; clavulanate potassium) 600/5mL, NDA 50-755, manufactured by SmithKline Beecham was withdrawn from sale for reasons	505(q)	2010-03-31	Denied	—

Source: Regulations.gov. FDA citizen petitions matched by application number.

Clinical Trials

76 trials from ClinicalTrials.gov — 1 recruiting, 50 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia NCT02735707	Phase 3	Recruiting	UMC Utrecht	20,000	2016-04-11 → 2028-02
A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization NCT00797108	Phase 2	Completed	Pfizer	35	2009-01 → 2009-06
Trial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia NCT02258763	Phase 4	Completed	University of Malaya	19	2014-11 → 2018-10
Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children NCT02891915	Phase 4	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	385	2016-12-02 → 2019-12-16
Effect of Preoperative Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain NCT03033147	N/A	Completed	Cairo University	72	2019-10-18 → 2020-03-15
Antibiotic Therapy in Erupted Tooth Extractions NCT04082598	Phase 4	Completed	Antonio Barone	165	2016-10-01 → 2019-01-30
Reduction of Intravenous Antibiotics In Neonates NCT03247920	Phase 4	Completed	Franciscus Gasthuis	510	2017-11-04 → 2021-07-15
Maxillary Sinus Irrigation in the Management of Chronic Rhinosinusitis NCT00335309	N/A	Completed	Ohad Ronen	50	2005-10 → 2013-08
Guidelines for Acute Sinusitis NCT00132275	N/A	Completed	University of Pittsburgh	240	2003-11 → 2006-08
A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months NCT03818815	Phase 2	Completed	Novus Therapeutics, Inc	103	2019-02-21 → 2020-03-26

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$0.0696

per ml

Lowest NADAC/Unit

$0.0609

per ml

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
81964020351AMOX-CLAV 600-42.9 MG/5 ML SUS	$0.0696	ML	Generic	—	2026-06-17
81964020369AMOX-CLAV 600-42.9 MG/5 ML SUS	$0.0626	ML	Generic	—	2026-06-17
81964020354AMOX-CLAV 600-42.9 MG/5 ML SUS	$0.0609	ML	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 3 NDCs (3 FSS)

Lowest Price

$0.01

Highest Price

$1.22

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
81964-0203-51AMOXICILLIN TRIHYRATE 600MG/CLAVULANATE K 42.	$0.99	FSS	USAntibiotics LLC	03/31/2028
81964-0203-54AMOXICILLIN TRIHYRATE 600MG/CLAVULANATE K 42.	$0.01	FSS	USAntibiotics LLC	03/31/2028
81964-0203-69AMOXICILLIN TRIHYRATE 600MG/CLAVULANATE K 42.	$1.22	FSS	USAntibiotics LLC	03/31/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Approval Letters

14 letters from Drugs@FDA

Date	Submission	Document
Dec 26, 2024	SUPPL -31	View Letter (PDF)
May 2, 2024	SUPPL -29	View Letter (PDF)
Sep 23, 2022	SUPPL -25	View Letter (PDF)
Jul 1, 2022	SUPPL -24	View Letter (PDF)
Mar 17, 2015	SUPPL -22	View Letter (PDF)
Aug 31, 2011	SUPPL -18	View Letter (PDF)
Aug 31, 2011	SUPPL -16	View Letter (PDF)
Jan 26, 2009	SUPPL -14	View Letter (PDF)
Apr 22, 2008	SUPPL -15	View Letter (PDF)
Dec 30, 2004	SUPPL -12	View Letter (PDF)
Nov 16, 2004	SUPPL -11	View Letter (PDF)
Jun 7, 2004	SUPPL -10	View Letter (PDF)
Jun 8, 2003	SUPPL -3	View Letter (PDF)
Jun 26, 2001	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 600MG/5ML;EQ 42.9MG BASE/5ML

RLDAB

0 patents0 exclusivities▴

FOR SUSPENSION;ORAL | Approved: Jun 22, 2001

No patent or exclusivity listings for this strength.